Improved R2* measurement in myocardial iron overload

Journal of Magnetic Resonance Imaging

Volumn 23, Issue 1, 2006, Pages 9-16

  Ghugre, Nilesh R ^a,b   Enriquez, Cathleen M ^a   Coates, Thomas D ^a   Nelson Jr , Marvin D ^b   Wood, John C ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Heart; Iron; Myocardium; Relaxivity (R2*); Susceptibility artifact

Indexed keywords

APPARATUS; ARTICLE; ARTIFACT; BLOOD TRANSFUSION; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HEART MUSCLE RELAXATION; HEART VENTRICLE SEPTUM; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSCILLATION; PRIORITY JOURNAL; RELAXATION TIME; SICKLE CELL ANEMIA; SIGNAL DETECTION; THALASSEMIA MAJOR; TIME; HEART MUSCLE; METABOLISM; METHODOLOGY; PATHOLOGY; THALASSEMIA;

ANEMIA, SICKLE CELL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; THALASSEMIA;

EID: 30744450021     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20467     Document Type: Article

References (30)

1. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-578.
2. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
3. Kremastinos DT, Toutouzas PK, Vyssoulis GP, Venetis CA, Avgoustakis DG. Iron overload and left ventricular performance in beta thalassemia. Acta Cardiol 1984;39:29-40.
4. Kremastinos DT, Toutouzas PK, Vyssoulis GP, Venetis CA, Vretou HP, Avgoustakis DG. Global and segmental left ventricular function in beta-thalassemia. Cardiology 1985;72:129-139.
5. Ehlers KH, Levin AR, Markenson AL, et al. Longitudinal study of cardiac function in thalassemia major. Ann N Y Acad Sci 1980;344:397-404.
6. Cecchetti G, Binda A, Piperno A, Nador F, Fargion S, Fiorelli G. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J 1991;12:224-230.
7. Jessup M, Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia. Ann N Y Acad Sci 1998;850:242-250.
8. Wood JC, Tyszka JM, Ghugre N, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood 2004;103:1934-1936.
9. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632-4639.
10. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
11. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-520.
12. Reeder SB, Faranesh AZ, Boxerman JL, McVeigh ER. In vivo measurement of T*2 and field inhomogeneity maps in the human heart at 1.5 T. Magn Reson Med 1998;39:988-998.
13. Olson LJ, Edwards WD, McCalI JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987;10:1239-1243.
14. Olson LJ, Edwards WD, Holmes Jr DR, Miller Jr FA, Nordstrom LA, Baldus WP. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J Am Coll Cardiol 1989;13:116-120.
15. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971;51:209-221.
16. NessAiver M. Breath-hold eines using phase encode grouping. In: Pohost GM, ed. Cardiovascular applications of magnetic resonance. Mount Kisco, NY: Futura Publishing: 1993. p 33-145.
17. Li HF, Clarke GD, Nessaiver M, Liu HY, Peshock R. Magnetic resonance imaging K-space segmentation using phase-encoding groups-the accuracy of quantitative measurements of pulsatile flow. Med Phys 1995;22:391-399.
18. Coleman TF, Li YY. An interior trust region approach for nonlinear minimization subject to bounds. Siam J Optimization 1996;6:418-445.
19. Haacke EM, Brown RW, Thompson MR, Venkatesan R. Magnetic resonance imaging: physical principles and sequence design. New York: Wiley-Liss: 1999. 914 p.
20. Westwood MA, Anderson LJ, Tanner MA, Pennell DJ. The relationship between myocardial iron deposition and left ventricular dysfunction in thalassemia using cardiovascular magnetic resonance. JCMR 2005;7:46-47.
21. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
23. Li D, Wang Y, Waight DJ. Blood oxygen saturation assessment in vivo using T2* estimation. Magn Reson Med 1998;39:685-690.
24. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cell disease patients. Blood 2005;106:1460-1465.
25. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.
26. Bulte JW, Miller GF, Vymazal J, Brooks RA, Frank JA. Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn Reson Med 1997;37:530-536.
27. Liu P, Henkelman M, Joshi J, et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Can J Cardiol 1996;12:155-164.
28. Thomsen C, Wiggers P, Ring-Larsen H, et al. Identification of patients with hereditary haemochromatosis by magnetic resonance imaging and spectroscopic relaxation time measurements. Magn Reson Imaging 1992;10:867-879.
29. St Pierre TG. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003;361:182: author reply 183-184.
30. Wacker CM, Bock M, Hartlep AW, et al. Changes in myocardial oxygenation and perfusion under pharmacological stress with dipyridamole: assessment using T*2 and T1 measurements. Magn Reson Med 1999;41:686-695.